Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI - Free Report) or West Pharmaceutical Services (WST - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Both Merit Medical and West Pharmaceutical Services have a Zacks Rank of #2 (Buy) right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that these stocks have improving earnings outlooks. But this is only part of the picture for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
MMSI currently has a forward P/E ratio of 18.19, while WST has a forward P/E of 41.65. We also note that MMSI has a PEG ratio of 2.05. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. WST currently has a PEG ratio of 2.90.
Another notable valuation metric for MMSI is its P/B ratio of 2.71. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, WST has a P/B of 8.46.
Based on these metrics and many more, MMSI holds a Value grade of B, while WST has a Value grade of D.
Both MMSI and WST are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that MMSI is the superior value option right now.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 17.46; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
Key Takeaways MMSI is positioned for growth with its strong product portfolio, acquisitions and R&D investments.MMSI launched Resilience and acquired View Point, expanding oncology and endoscopy opportunities.MMSI faces tariff costs, China pricing pressure and OEM demand fluctuations in the near term. Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expected to contribute further. However, tariffs and trade policy headwinds, and China macro pressure persist.
This Zacks Rank #2 (Buy) company’s shares have declined 19.4% in the year-to-date period compared with the industry’s 1.2% drop. However, the S&P 500 has risen 9.5% during the same time frame.
The renowned medical device provider has a market capitalization of $4.30 billion. The company projects 8.9% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 12.5% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
MMSI’s Growth DriversStrong Product Portfolio and Strategic Acquisitions: Merit Medical continues to expand its presence across interventional cardiology, radiology, oncology, endoscopy and other minimally invasive procedure markets through a diversified product portfolio and disciplined acquisitions. During the first quarter of 2026, the company launched the Resilience Through-the-Scope Esophageal Stent, which management expects to support long-term growth in its endoscopy business. Merit Medical also acquired View Point Medical, adding the OneMark Detection Imaging System and Tissue Markers to complement its SCOUT platform. Management believes the acquisition expands the addressable procedure opportunity for its oncology business by roughly threefold while providing physicians with additional localization options. Earlier acquisitions, including Biolife and the C2 CryoBalloon technology, continue to strengthen the company's therapeutic portfolio and support long-term growth.
Innovation-Driven R&D: Merit Medical continues to invest in research and development to expand its product pipeline and strengthen its competitive position. The company has reorganized its R&D, marketing and commercial teams around eight product platforms, enabling faster product development and closer alignment with physician needs. Supported by approximately 2,200 patents and patent applications, Merit Medical follows a disciplined innovation strategy that prioritizes products with strong commercial potential and attractive returns, positioning the company for sustained long-term growth.
WRAPSODY Offers Long-Term Upside: Merit Medical's WRAPSODY Cell-Impermeable Endoprosthesis remains an important long-term growth opportunity within renal therapies. Clinical data continue to demonstrate superior long-term vessel patency compared with conventional angioplasty, supporting broader physician adoption. Management reaffirmed its commercial strategy and expects the product to generate approximately $7 million in revenues in the United States in 2026. While adoption remains in the early stages, continued physician education and expanding clinical evidence position WRAPSODY as a meaningful multi-year growth catalyst.
Key Challenges for MMSI StockTariffs and Macroeconomic Uncertainty: Merit Medical continues to operate in an uncertain macroeconomic environment marked by evolving trade policies and geopolitical risks. During the first quarter earnings call, management highlighted tariffs as a significant headwind and expects them to remain a drag on profitability in 2026. While the company has implemented operational initiatives to offset part of the cost pressure, the ultimate impact remains uncertain as it depends on future tariff policies, retaliatory actions and legal developments. Geopolitical disruptions, including those affecting the Middle East, have created temporary shipping delays and higher freight-related costs. Although management described these challenges as manageable, prolonged macroeconomic uncertainty could pressure margins and weigh on earnings growth.
OEM and Pricing Headwinds: Merit Medical continues to face near-term pressure in its OEM business, which has experienced demand fluctuations due to inventory destocking, product line transfers and softer international demand, particularly in the Asia-Pacific region. Management expects these issues to be temporary and continues to view the OEM business as a mid- to high-single-digit grower over the long term. However, broader pricing pressure remains a challenge. The company continues to navigate China's volume-based procurement program, which has reduced pricing in recent years and is expected to remain a headwind in 2026. As Merit Medical expands its therapeutic portfolio through acquisitions and new product launches, sustaining growth will require continued innovation and disciplined execution.
Estimate TrendMMSI is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has remained stable at $4.07.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $404.7 million, suggesting a 5.81% rise from the year-ago reported number. The consensus mark for EPS is pegged at 96 cents, implying a 4.9% decline from the prior-year reported figure.
Other Stocks to ConsiderSome other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Pacific Biosciences of California (PACB - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated earnings growth rate of 5.1% for 2026. VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte’s shares have gained 33.3% against the industry’s 14.2% decline in the year-to-date period.
West Pharmaceutical, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
West Pharmaceutical’s shares have gained 28.5% against the industry’s 1.2% decline in the year-to-date period.
Pacific Biosciences of California, currently carrying a Zacks Rank #2, has an estimated earnings growth rate of 22.6% for 2026. PACB’s earnings beat estimates in each of the trailing four quarters, the average surprise being 29.8%.
Pacific Biosciences’ shares have lost 19.8% compared with the industry’s 14.2% decline in the year-to-date period.
July 02, 2026 16:05 ET | Source: Merit Medical Systems, Inc.
SOUTH JORDAN, Utah, July 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2026, after the close of the stock market on Thursday, July 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, July 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).
To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.
A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com.
ABOUT MERIT
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Merit Medical (MMSI) and West Pharmaceutical Services (WST). But which of these two stocks offers value investors a better bang for their buck right now?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. MMSI has a Momentum Style Score of B, and shares are up 4.8% over the past four weeks.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $4.07 per share. MMSI also boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MMSI should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $4.07 per share. MMSI also boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.54; value investors should take notice.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $4.07 per share. MMSI also boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company conducts its business via two operating segments: Cardiovascular (which includes Peripheral Intervention or PI, Cardiac Intervention or CI, Custom Procedural Solutions or CPS and Original Equipment Manufacturer or OEM and Endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.68; value investors should take notice.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $4.07 per share. MMSI also boasts an average earnings surprise of +13.2%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company conducts its business via two operating segments: Cardiovascular (which includes Peripheral Intervention or PI, Cardiac Intervention or CI, Custom Procedural Solutions or CPS and Original Equipment Manufacturer or OEM and Endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.02 to $4.07 per share. MMSI boasts an average earnings surprise of +13.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
On April 13, 2026, Merit Medical Systems Inc MMSI shares rose 3.4% today, trading at $70.57. The stock has experienced a 52-week range between $66.34 and $100.19, reflecting a volatile trading environment.
GF Value™ verdict: Current price of $70.57 is 26.5% below the GF Value™ estimate of $96.06.GF Score™: 85/100, indicating a strong overall position based on multiple financial metrics.Most notable signal: The momentum rank is low at 2/10, suggesting recent price weakness. Is MMSI Overvalued or Undervalued? Based on the current trading price of $70.57 and the GF Value™ estimate of $96.06, Merit Medical Systems Inc presents a significant margin of safety, standing at 26.5% undervalued. This undervaluation indicates a potential opportunity for investors, as the stock price is well below its intrinsic value according to GuruFocus’ assessment. The GF Valuation label describes MMSI as "Modestly Undervalued," suggesting that while there is an attractive entry point, investors should be cautious of market volatility and the current low momentum rank.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. This method provides a comprehensive view of the company's potential worth, which, in this case, suggests that the stock could recover and align more closely with its estimated fair value over time.
How Does MMSI's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 33.3x 50.1x Forward P/E 17.4x N/A Currently, MMSI's P/E (TTM) of 33.3x is significantly below its 5-year median P/E of 50.1x, indicating that the stock is trading at a lower valuation compared to its historical performance. The forward P/E of 17.4x further emphasizes this disparity, suggesting potential for future earnings growth. This P/E analysis aligns with the GF Value™ verdict that suggests MMSI is undervalued, supporting the notion that there may be room for appreciation if the company meets its growth expectations.
What Does MMSI's GF Score™ Tell Us? Metric Rating GF Score™ 85 Financial Strength 7/10 Profitability 8/10 Growth 9/10 Valuation 8/10 Momentum 2/10 The GF Score™ of 85/100 reflects a strong overall position for Merit Medical Systems Inc, particularly in the categories of Growth (9/10) and Profitability (8/10). These scores suggest that the company has performed well in generating profits and is likely to sustain growth in the future. However, the low Momentum rank of 2/10 indicates recent underperformance, which may deter some investors. Overall, while the fundamentals appear solid, the current momentum weakness should be considered by those evaluating the stock.
What Are Insiders Doing with MMSI Stock? In the last three months, there have been no insider transactions reported for Merit Medical Systems Inc. This lack of trading activity from insiders may indicate a level of confidence in the current valuation and future prospects of the company. However, it may also suggest a lack of immediate catalysts for significant price movement in the short term.
What This Means for Investors Based on the GF Value™ estimate, Merit Medical Systems Inc is currently undervalued. The significant margin of safety suggests potential upside for investors willing to navigate the current market volatility. However, the low momentum rank and lack of insider activity may warrant a cautious approach when considering an investment in MMSI.
For the complete analysis, visit the Merit Medical Systems Inc MMSI stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MMSI's GF Score™?
MMSI has a GF Score™ of 85/100, indicating a strong overall position based on financial metrics and historical performance.
Is MMSI overvalued or undervalued?
According to the GF Value™ estimate, MMSI is undervalued by 26.5%, suggesting significant upside potential based on its intrinsic value.
What is MMSI's P/E ratio?
The current P/E (TTM) ratio for MMSI is 33.3x, which is 34% below its 5-year median P/E of 50.1x, indicating a lower valuation compared to its historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Key Takeaways MMSI growth is driven by strong cardiovascular and peripheral intervention device demand.Therapeutic products outpace foundational offerings, with faster CAGR and rising adoption.Tariffs, China weakness and OEM declines are pressuring margins and near-term growth. Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expected to contribute further. However, tariffs and trade policy headwinds, and China macro pressure persist.
This Zacks Rank #3 (Hold) company’s shares have declined 20% in the year-to-date period compared with the industry’s 1.8% drop. However, the S&P 500 has risen 0.5% during the same time frame.
The renowned medical device provider has a market capitalization of $4.21 billion. The company projects 9.5% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 13.2% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
MMSI’s Growth DriversStrength in Cardiovascular & Peripheral Intervention Devices: The cardiovascular segment remains the main growth engine for Merit Medical, showing strong results driven by cardiac and peripheral intervention products. Cardiac intervention sales remain supported by demand for electrophysiology, cardiac rhythm management, angiography and vascular access offerings.
Peripheral intervention product growth is driven by strong sales in radar localization and delivery systems, reflecting wider adoption across embolotherapy, drainage, angiography and access categories. This momentum is expected to persist into 2026.
Expansion of Therapeutic Products & Innovation: Merit Medical’s therapeutic portfolio is outpacing its foundational products, emerging as a growth driver. Foundational products delivered a 6% CAGR over the past three years. In comparison, therapeutic products have grown with a 19% CAGR over the same period. This segment has become a major growth driver, reflecting rising physician adoption of devices that focus on treatment rather than procedural support.
Product Innovation & Acquisitions: Growth in 2025 was supported by a mix of internal product development and acquisitions. Product launches such as the Resilience Through-the-Scope Esophageal Stent, Prelude SNAP system, Ventrax Delivery System, Prelude radial sheath and SCOUT radar localization system gained traction. The recent acquisition of View Point Medical is projected to generate between $2 million and $4 million in revenues in 2026.
Key Challenges for MMSI StockTariffs & Trade Policy Pressuring Margins: Tariffs weighed on gross margin performance in fourth-quarter 2025, with a 112-basis-point year-over-year impact. Management expects this pressure to continue into 2026. Guidance for the year includes a projected tariff impact of $15 million, or 19 cents per share, compared with $9 million, or 12 cents per share, recorded during the last eight months of 2025.
In the near term, tariffs are expected to create an 80-basis-point, or $3 million, gross margin impact in first-quarter 2026, which adds uncertainty around future cost pressure and margin performance.
OEM Weakness & China Macro Pressure: The company saw weakness in its OEM business in the United States due to softer performance driven by customer inventory destocking, which reduced order volumes from OEM partners. Outside the United States, demand faced pressure in China due to the impact of the country’s volume-based procurement program, which has pressured pricing across medical device categories.
Despite near-term volatility, the company expects the OEM segment to return to a mid- to high-single-digit growth range over time, though near-term fluctuations may persist.
Estimate TrendMMSI is witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved 0.5% north to $4.07.
The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pegged at $377.5 million, suggesting a 6.23% rise from the year-ago reported number. The consensus mark for EPS is pegged at 84 cents, implying a 2.3% decline from the prior-year reported figure.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Cardinal Health (CAH - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated earnings recession rate of 1.9%. PACB’s earnings surpassed estimates in the trailing four quarters, the average surprise being 27.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pacific Biosciences’ shares have lost 16% compared with the industry’s 12.9% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 15%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.3%.
Cardinal Health’s shares have gained 4.6% against the industry’s 1.9% decline in the year-to-date period.
GE HealthCare Technologies, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 9.1%. GEHC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 7.5%.
GE HealthCare Technologies’ shares have lost 9% compared with the industry’s 13.4% decline in the year-to-date period.
Financial Highlights† Reported revenue of $381.9 million, up 7% Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year period Non-GAAP operating margin* of 19.7%, compared to 19.3% in prior year period GAAP EPS $0.68, up 39% Non-GAAP EPS* $0.94, up 9% Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25.5 million was paid in cash at closing On April 1, 2026, Merit acquired View Point Medical, Inc., manufacturer of the OneMark® Detection Imaging System and OneMark Tissue Markers, for $140 million, of which $90 million was paid in cash at closing Beginning in the first quarter of 2026, Merit reorganized the presentation of revenue into two product categories – Foundational and Therapeutic - to better reflect the clinical uses of our diverse portfolio of products** † Comparisons above are calculated for the current quarter compared with the first quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.
Merit Medical (MMSI - Free Report) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.86 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +12.13%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.96 per share when it actually produced earnings of $1.04, delivering a surprise of +8.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Merit Medical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $381.88 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.28%. This compares to year-ago revenues of $355.35 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Merit Medical shares have lost about 26.4% since the beginning of the year versus the S&P 500's gain of 4.2%.
What's Next for Merit Medical?While Merit Medical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Merit Medical was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $411.1 million in revenues for the coming quarter and $4.04 on $1.61 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Dentsply International (XRAY - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 5.
This dental products manufacturer is expected to post quarterly earnings of $0.28 per share in its upcoming report, which represents a year-over-year change of -34.9%. The consensus EPS estimate for the quarter has been revised 3.9% lower over the last 30 days to the current level.
Dentsply International's revenues are expected to be $840.06 million, down 4.4% from the year-ago quarter.
Key Takeaways MMSI posted Q1 EPS of 94 cents, beating estimates by 11.9% and rising 9% year over year.Revenues reached $381.9M, up 7%, driven by growth in both Foundational and Therapeutic segments.MMSI raised 2026 revenue outlook to $1.612-$1.634B while maintaining EPS guidance of $4.01-$4.15. Merit Medical Systems, Inc. (MMSI - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of 94 cents, up 9% from the year-ago quarter’s level. The bottom line surpassed the Zacks Consensus Estimate by 11.9%.
GAAP EPS for the quarter was 63 cents, up 39% year over year.
MMSI’s Revenue DetailsRevenues amounted to $381.9 million in the reported quarter, up 7% year over year on a reported basis. The metric topped the Zacks Consensus Estimate by 1.3%.
Total revenues at constant exchange rate (CER) increased 5.2% year over year, whereas CER organic revenues improved 3.7%.
Merit Medical’s Geographic ResultsThe U.S. sales amounted to $226.5 million, which increased 6.1% year over year on a reported basis and 6.8% at CER. Our first-quarter projection was $228 million for the metric.
International sales amounted to $155.4 million, up 9.6% year over year on a reported basis and 2.9% at CER. This figure compares to our projection of $148.7 million.
MMSI’s Segmental DetailsBeginning first-quarter 2026, Merit Medical started operating through two product categories — Foundational (67% of sales) and Therapeutic (33% of sales). Foundational products are used primarily for access and enabling functions in vascular and other procedures. Therapeutic products include devices and systems. The company previously reported under two categories — Cardiovascular and Endoscopy.
The Foundational category reported first-quarter revenues of $255.5 million, up 6% on a reported basis and 4% at CER year over year.
Therapeutic unit’s revenues totaled $126.4 million, up 10% year over year on a reported basis and 5% at CER.
Merit Medical’s Margin AnalysisIn the quarter under review, Merit Medical’sgross profit increased 7.4% year over year to $184.8 million. The adjusted gross margin contracted 20 basis points (bps) to 53.2%. We had projected a 53.3% gross margin for the first quarter.
Selling, general & administrative expenses increased 10% year over year to $118.2 million. Research and development expenses rose 0.6% year over year to $22.6 million.
Operating profit totaled $44.2 million, reflecting a 7.6% increase from the prior-year quarter’s level. The adjusted operating margin in the first quarter expanded 40 bps to 19.7%.
MMSI’s Financial PositionMerit Medical exited first-quarter 2026 with cash and cash equivalents of $488.1million compared with $446.4 million at the end of the fourth quarter of 2025. Total long-term debt at the end of the first quarter was $735.2 million compared with $734 million in the previous quarter.
Cumulative net cash provided by operating activities at the end of first-quarter 2026 was $40.7 million compared with $40.6 million a year ago.
Merit Medical’s GuidanceMMSI has updated its outlook for2026.
Net revenues for 2026 are projected to be between $1.612billion and $1.634 billion (reflecting an increase of 6-8% year over year on a reported basis), up from the previous guidance of $1.610-$1.630 billion. The Zacks Consensus Estimate is pegged at $1.61 billion.
The company has maintained its guidance for 2026 adjusted EPS of $4.01-$4.15 (implying an increase of 5-8% year over year). The Zacks Consensus Estimate is pegged at $4.04.
Our Take on MMSIMerit Medical exited the first quarter of 2026 with better-than-expected results. The year-over-year uptick in the top and bottom lines was impressive. The company’s organic growth remained modest at 2.7% (3.7% ex-divestiture), but was supplemented by acquisitions. Profitability stood out as operating margin expanded to a record 19.7% and EPS grew 9%, both ahead of guidance. Free cash flow increased 26%, reflecting disciplined cost control and improving operational execution.
Looking ahead, growth should be supported by expansion in higher-growth therapeutic segments, new product launches such as the Resilience stent, and the View Point Medical acquisition, which strengthens the oncology platform and expands addressable markets. However, challenges persist, including OEM revenue volatility, tariff-related margin pressure, and macro headwinds in APAC. The DualCap divestiture and near-term acquisition may weigh on growth and earnings cadence. Despite these factors, management maintains confidence in steady growth and margin improvement through 2026.
Merit Medical’s shares have lost 22.6% so far this year compared with the industry’s decline of 6%. The S&P 500 Index has risen 4.5% in the same period.
Image Source: Zacks Investment Research
Merit Medical’s Zacks Rank and Key PicksMerit Medical currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy) at present, Phibro Animal Health and Cardinal Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical’s shares have gained 3.3% in the year-to-date period. Estimates for the company’s first-quarter 2026 EPS have increased 1 cent to 90 cents in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 18.79%. In the last reported quarter, it posted an earnings surprise of 20.75%.
Estimates for Phibro Animal Health’s third-quarter fiscal 2026 EPS have remained constant at 72 cents in the past 30 days. Shares of the company have risen 42.4% in the year-to-date period against the industry’s 20.5% decline. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.15%. In the last reported quarter, it delivered an earnings surprise of 26.09%.
Cardinal Health’s shares have declined 6.2% in the year-to-date period. Estimates for the company’s third-quarter 2026 EPS have decreased 1 cent to $2.80 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.30%. In the last reported quarter, it posted an earnings surprise of 10.04%.
Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company conducts its business via two operating segments: Cardiovascular (which includes Peripheral Intervention or PI, Cardiac Intervention or CI, Custom Procedural Solutions or CPS and Original Equipment Manufacturer or OEM and Endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.33; value investors should take notice.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.00 to $4.05 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
May 08, 2026 09:25 ET | Source: Merit Medical Systems, Inc.
SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit management will participate in the Bank of America 2026 Health Care Conference, to be held in Las Vegas, Nevada, May 12-14, 2026.
The management team will participate in a fireside chat session on Tuesday, May 12th at 3:00 pm Pacific Time / 6:00 pm Eastern Time.
A live audio webcast of the fireside chat will be accessible under the “Events” section of the Company’s investor relations website at Investor Events and Presentations - Merit Medical. A replay of the fireside chat will be available on this same website for approximately 90 days.
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.
Lynne N. Ward, Director at Merit Medical Systems (MMSI 0.76%), reported an open-market sale of 5,000 shares for a total of approximately $313,000, according to the SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)5,000Transaction value~$313,000Post-transaction shares (direct)7,809Post-transaction value (direct ownership)~$489,000Transaction and post-transaction value based on SEC Form 4 weighted average purchase price ($62.61).
Key questionsHow did the transaction affect Lynne Ward's ownership in Merit Medical Systems?
The sale reduced Ward's direct holdings by 39%, from 12,809 shares to 7,809 shares, with no remaining indirect or derivative securities reported.Were any other forms of disposition, such as gifts or withholdings, involved in this filing?
No; the filing strictly reflects a direct open-market sale, with no gifts or shares withheld for taxes or administrative purposes.What does the transaction size indicate about Ward's trading pattern and remaining capacity?
The 5,000-share sale is the only open-market sale in the last twelve months and reflects a larger proportion of Ward's shrinking available holdings, consistent with the ongoing reduction in position size.What continuing interest does Ward have in Merit Medical Systems following this sale?
Despite the reduction, Ward retains 7,809 shares of Common Stock (direct), maintaining a continuing ownership position.Company overviewMetricValueRevenue (TTM)$1.54 billionNet income (TTM)$139.34 millionEmployees7,4001-year price change(36.06%)* 1-year price change calculated using May 7, 2026 as the reference date.
Company snapshotMerit Medical Systems designs, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, with a focus on cardiology, radiology, oncology, critical care, and endoscopy.It generates revenue through the direct sale and distribution of proprietary medical devices and custom procedural solutions to healthcare providers and OEM partners.The company serves hospitals, physicians, technicians, and nurses in the United States and international markets through a combination of direct sales and distributor relationships.Merit Medical Systems, Inc. is a leading provider of single-use medical devices, operating at scale with over 7,400 employees and a global footprint. The company's strategy centers on innovation in minimally invasive procedures and procedural efficiency, supporting its competitive position in the medical instruments and supplies sector.
Merit Medical's diversified product portfolio and broad customer base drive consistent demand across major healthcare markets.
What this transaction means for investorsThe May 7 sale of Merit Medical stock by Board of Directors member Lynne Ward comes at a time when shares were on the decline. The stock eventually hit a 52-week low of $59.74 on May 12, not long after War’s disposition, and far from an ideal time to sell.
The price drop was due to Wall Street’s concerns over macroeconomic headwinds. Higher tariffs, in particular, can hurt Merit Medical’s business performance.
Another investor concern is decelerating growth. Merit’s 2026 guidance of about $1.6 billion in sales was not a large step up from the prior year’s $1.5 billion, when the company experienced a 12% year-over-year increase.
Over the long term, Merit Medical shares can recover, once macroeconomic headwinds pass. That may be one reason why Lynne Ward held on to 7,809 shares after her sale, suggesting the May 7 disposition may have been for personal reasons, and not a lack of faith in the company’s long-term success.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
May 19, 2026 09:15 ET | Source: Merit Medical Systems, Inc.
SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders elected Scott R. Ward to the company’s Board of Directors at Merit’s annual meeting of shareholders.
Mr. Ward was elected to serve a three-year term.
“On behalf of the Board, we are pleased with Scott Ward’s election to Merit’s Board of Directors,” said F. Ann Millner, Merit’s Chair of the Board. “Scott’s extensive industry experience, strategic insight, and commitment to innovation will be tremendous assets as we continue advancing the company’s strategic priorities.”
“We are proud to welcome Scott Ward to Merit’s Board,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “Scott brings deep medical device experience and a proven leadership track record. As we continue building on our foundation and advancing our strategy, his perspective will be invaluable to our long-term growth.”
“I am honored to join the Merit Board of Directors,” Ward said. “I have great respect for Merit’s commitment to innovation and its focus on serving patients and healthcare providers around the world. I look forward to contributing my experience as the company continues to grow and expand its impact.”
Mr. Ward brings more than 40 years of experience in the healthcare and medical device industry, including nearly three decades at Medtronic, where he held senior leadership roles such as senior vice president and president of the cardiovascular, neurological, and diabetes businesses. He most recently served as CEO, President and Chairman of Cardiovascular Systems, Inc., leading the company through a period of expansion and its acquisition by Abbott.
Mr. Ward is also the founder of Raymond Holdings, a firm focused on venture capital, strategy, and advisory services for medical technology and life sciences companies, and has served on numerous public and private company boards. Merit’s Board of Directors has appointed Mr. Ward to serve on its Governance and Sustainability and Finance and Operating Committees.
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.00 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
On May 27, 2026, Merit Medical Systems Inc MMSI shares fell 3.1% to a current price of $62.52. This decline is part of a broader trend, with the stock down 29.1% year-to-date and 35.2% over the past year, while trading within a 52-week range of $59.74 to $97.18.
GF Value™ verdict: The current price is $62.52, which is 35.0% below the GF Value™ estimate of $96.19.GF Score™: At 79/100, the stock is rated as Above Average, indicating potential for long-term returns.Most notable signal: Insider activity shows that insiders bought $0.6M and sold $0.3M in the last 3 months, indicating some level of confidence in the company’s prospects. Is MMSI Overvalued or Undervalued? The GF Value™ of Merit Medical Systems Inc MMSI is estimated at $96.19, suggesting that the stock is currently undervalued at a price of $62.52. This presents a margin of safety of 35.0%, indicating a significant upside potential. The GF Valuation label classifies the stock as significantly undervalued, which implies that the market may not be fully recognizing the company’s growth prospects and financial health. However, while the undervaluation presents an opportunity, investors should remain cautious, as fluctuations in market sentiment or company performance could impact this valuation.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Therefore, the current price level could be viewed as an attractive entry point for long-term investors, provided that the company's fundamentals remain strong and the broader market conditions are favorable.
How Does MMSI's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 27.1x 49.1x Forward P/E 15.4x N/A The current P/E (TTM) of 27.1x is significantly below its 5-year median P/E of 49.1x, indicating that MMSI is trading at a discount compared to its historical valuation. Additionally, the forward P/E of 15.4x suggests further potential for growth. This P/E analysis aligns with the GF Value™ verdict of undervaluation, reinforcing the notion that the stock may be undervalued relative to its historical performance.
What Does MMSI's GF Score™ Tell Us? Metric Rating GF Score™ 79 Financial Strength 7/10 Profitability 8/10 Growth 9/10 Valuation 4/10 Momentum 2/10 The GF Score™ of 79 indicates that Merit Medical Systems Inc MMSI has solid fundamentals, particularly in Growth (9/10) and Profitability (8/10), suggesting the company has the potential to generate strong returns. However, the Valuation score of 4/10 and a Momentum rank of 2/10 highlight areas of concern, indicating that while the underlying business may be strong, the stock may lack the momentum needed to attract new investors in the short term.
What Are Insiders Doing with MMSI Stock? In the past three months, there has been notable insider activity at Merit Medical Systems Inc MMSI , with insiders purchasing $0.6 million worth of shares while also selling $0.3 million. This pattern of buying amidst some selling may suggest that insiders are optimistic about the company's future performance, as they are willing to increase their stake even while realizing some profits. Such insider buying can be viewed as a positive signal about the company’s prospects.
What This Means for Investors Based on the GF Value™ assessment, Merit Medical Systems Inc MMSI is currently undervalued. At a current price of $62.52 compared to an estimated GF Value™ of $96.19, there is a substantial margin for potential upside. However, investors should also consider the factors impacting the stock's momentum and the broader market environment.
For the complete analysis, visit the Merit Medical Systems Inc MMSI stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MMSI's GF Score™?
MMSI has a GF Score™ of 79/100, indicating that it has strong potential for long-term returns based on its financial health and growth prospects.
Is MMSI overvalued or undervalued?
According to GF Value™, MMSI is undervalued, with a current price of $62.52 being 35.0% below the estimated fair value of $96.19.
What is MMSI's P/E ratio?
The current P/E (TTM) for MMSI is 27.1x, which is significantly lower than its 5-year median P/E of 49.1x, suggesting it is trading at a discount compared to its historical average.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.26; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.00 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
Key Takeaways MMSI beat Q1 2026 constant-currency revenue expectations as therapeutic product sales rose 7% YoY.MMSI acquired View Point Medical to expand oncology; OneMark is projected to add $2-$4M in revenues in 2026.MMSI said tariffs cut Q1 gross margin by 120 bps; OEM revenues fell 14% and China pricing remains pressured. Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expected to contribute further. However, tariffs and trade policy headwinds, and China macro pressure persist.
This Zacks Rank #3 (Hold) company’s shares have declined 26.9% in the year-to-date period compared with the industry’s 6.5% drop. However, the S&P 500 has risen 8.1% during the same time frame.
The renowned medical device provider has a market capitalization of $3.85 billion. The company projects 8.9% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 12.5% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
MMSI’s Growth DriversStrength in Therapeutic Products and Core Platforms: Merit Medical delivered first-quarter 2026 constant-currency revenue growth above management’s expectations, supported by strong performance across its therapeutic product portfolio. Therapeutic product sales increased 7% year over year, driven by robust growth in cardiac therapies and endoscopy, along with solid contributions from vascular intervention and oncology products.
The company’s therapeutic business continues to be an important growth engine, representing roughly one-third of total revenues while growing faster than foundational products. Management highlighted that therapeutic products have delivered an 11% organic compound annual growth rate over the past three years, reflecting increasing physician adoption of products focused on disease treatment and intervention.
Oncology Expansion Through View Point Medical Acquisition: A major strategic development during the first quarter was Merit Medical’s acquisition of View Point Medical. The transaction expands the company’s oncology platform and strengthens its position in breast cancer localization procedures.
View Point Medical’s OneMark Detection Imaging System and tissue markers complement Merit Medical’s existing SCOUT platform. Management believes the acquisition expands the company’s addressable oncology procedure opportunity, targeting an estimated 1.3 million additional biopsy-related procedures annually in the United States.
The company expects the acquisition to contribute between $2 million and $4 million in revenues during 2026 and projects long-term annual sales growth of at least 20% for the OneMark platform.
Product Innovation Supporting Growth: Merit Medical continued to invest in product innovation across its therapeutic platforms. During the first quarter, the company commercially launched the Resilience Through-the-Scope Esophageal Stent, indicated for the treatment of esophageal fistulas and strictures caused by malignant tumors, in the United States. Management views the product as a differentiated offering that can support future growth.
The endoscopy business also benefited from the integration of the C2 CryoBalloon acquisition, which exceeded expectations during the quarter. Combined with the Resilience launch, these initiatives position the platform for continued growth.
Key Challenges for MMSI StockTariff-Related Cost Pressures: Despite strong operational execution, tariffs continue to pressure profitability. During the first quarter of 2026, tariffs reduced gross margin by 120 basis points and created a $4.6 million financial impact. While Merit Medical mitigated much of this pressure through pricing discipline, product mix improvements and operational efficiencies, management expects tariffs to remain a significant challenge throughout 2026.
Current guidance assumes a full-year tariff impact of approximately $15 million, or 19 cents per share, compared with a $9 million impact recorded during the final eight months of 2025. Although the company has begun seeking reimbursement for certain tariff payments, the outcome remains uncertain.
OEM Weakness & China Macro Pressure: The company’s OEM segment remained a drag on overall growth during the first-quarter 2026. OEM revenues declined 14% year over year due to inventory destocking by certain U.S. customers and continued demand softness in the Asia-Pacific region. Management characterized the weakness as largely temporary and timing-related rather than a loss of market share.
China also remains a challenging market due to the impact of volume-based procurement programs, which continue to pressure pricing across medical device categories. Although first-quarter performance in China was modestly better than expected, management continues to forecast only low-single-digit growth from the region in 2026.
Competitive Pressure Across Multiple Markets: Merit Medical faces competition from both large medical device companies and specialized niche players across its product portfolio. As the company expands through acquisitions and new product launches, it must continue driving innovation, maintaining market share and managing pricing pressures. Increased competition or slower integration of acquired businesses could create challenges for future growth and margin expansion.
Estimate TrendMMSI is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved 0.2% north to $4.07.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $404.7 million, suggesting a 6.81% rise from the year-ago reported number. The consensus mark for EPS is pegged at 96 cents, implying a 4.9% decline from the prior-year reported figure.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical’s shares have gained 14.3% against the industry’s 6.5% decline in the year-to-date period.
Globus Medical, currently sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Globus Medical’s shares have lost 8.4% compared with the industry’s 15.8% decline in the year-to-date period.
Biodesix, currently carrying a Zacks Rank of 2 (Buy), has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.
Biodesix’s shares have jumped 127.4% against the industry’s 8.1% decline in the year-to-date period.
Investors in Merit Medical Systems, Inc. (MMSI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the July 17, 2026 $90 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Merit Medical Systems shares, but what is the fundamental picture for the company? Currently, Merit Medical Systems is a Zacks Rank #3 (Hold) in the Medical - Dental Supplies industry that ranks in the Top 26% of our Zacks Industry Rank. Over the last 60 days, no analyst has increased the earnings estimates for the current quarter, while one has dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 97 cents per share to 96 cents in that period.
Given the way analysts feel about Merit Medical Systems right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
